{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.70","value":"8.0"},{"groupId":"OG001","spread":"0.55","value":"0.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Types of hospitals units considered to be 'higher care' are: - Intensive Care Unit - Coronary Care Unit","dispersionType":"Standard Deviation","groups":[{"description":"Luspatercept (ACE-536) was administered subcutaneously (SC) at a starting dose level of 1 mg/kg once every 21 days. Participants could be dose-titrated to 1.25 mg/kg, but the maximum total dose should not exceed 120 mg, total dose per administration during the Treatment Period, the Long-term Treatment Period, and Open-Label Treatment Period. BSC = Best Supportive Care","id":"OG000","title":"Luspatercept + BSC"},{"description":"Placebo (normal saline) was administered subcutaneously (SC) in volumes to match active treatment once every 21 days. BSC = Best Supportive Care","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEAN","populationDescription":"All randomized participants who spent time in higher care hospital units","reportingStatus":"POSTED","timeFrame":"From informed consent signing (up to 12 weeks before start of treatment) to end of treatment (up to approximately 227 weeks)","title":"Number of Days Spent in Higher Care Hospital Units","type":"SECONDARY","unitOfMeasure":"Days"}